Crealta Pharmaceuticals

Horizon Therapeutics PLC is building out its commercial plans for the launch of teprotumumab for the rare autoimmune condition thyroid eye disease (TED) in early 2020. Teprotumumab is pending at the

At 11:15 am on Aug. 17, the Health Resources & Services Administration released an advanced copy of a Federal Register notice proposing another delay in its final rule on calculating 340B drug price

Horizon Pharma PLC will continue to grow its orphan drug portfolio through acquisitions like the $800m purchase of Raptor Pharmaceutical Corp. announced on Sept. 12, but Horizon's primary care b

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions that occurred between Feb. 15 and M